Walvax BioTech - Asset Resilience Ratio

Latest as of June 2025: 2.20%

Walvax BioTech (300142) has an Asset Resilience Ratio of 2.20% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Walvax BioTech to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥308.17 Million
≈ $45.09 Million USD Cash + Short-term Investments

Total Assets

CN¥14.00 Billion
≈ $2.05 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2013–2022)

This chart shows how Walvax BioTech's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Walvax BioTech's balance sheet.

Liquid Assets Composition Over Time

This chart breaks down Walvax BioTech's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Walvax BioTech (300142) long-term investment share to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥308.17 Million 2.2%
Total Liquid Assets CN¥308.17 Million 2.20%

Asset Resilience Insights

  • Limited Liquidity: Walvax BioTech maintains only 2.20% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Walvax BioTech Industry Peers by Asset Resilience Ratio

Compare Walvax BioTech's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
Drug Manufacturers - Specialty & Generic 0.20%
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
Drug Manufacturers - Specialty & Generic 4.94%
Beijing Tongrentang Co Ltd
SHG:600085
Drug Manufacturers - Specialty & Generic 0.50%
Takeda Pharmaceutical Company Limited
F:TKDA
Drug Manufacturers - Specialty & Generic 0.69%
Changchun High & New Technology Industries Group Inc
SHE:000661
Drug Manufacturers - Specialty & Generic 5.50%
Neuland Laboratories Limited
NSE:NEULANDLAB
Drug Manufacturers - Specialty & Generic 9.65%
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062
Drug Manufacturers - Specialty & Generic 1.18%
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
Drug Manufacturers - Specialty & Generic 0.01%

Annual Asset Resilience Ratio for Walvax BioTech (2013–2022)

The table below shows the annual Asset Resilience Ratio data for Walvax BioTech.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2022-12-31 -0.25% CN¥-38.16 Million
≈ $-5.58 Million
CN¥15.34 Billion
≈ $2.24 Billion
+0.08pp
2021-12-31 -0.33% CN¥-45.05 Million
≈ $-6.59 Million
CN¥13.67 Billion
≈ $2.00 Billion
+0.17pp
2020-12-31 -0.50% CN¥-48.19 Million
≈ $-7.05 Million
CN¥9.65 Billion
≈ $1.41 Billion
+0.18pp
2019-12-31 -0.68% CN¥-47.52 Million
≈ $-6.95 Million
CN¥7.02 Billion
≈ $1.03 Billion
-0.12pp
2018-12-31 -0.56% CN¥-40.24 Million
≈ $-5.89 Million
CN¥7.24 Billion
≈ $1.06 Billion
+0.29pp
2017-12-31 -0.84% CN¥-49.59 Million
≈ $-7.26 Million
CN¥5.88 Billion
≈ $859.84 Million
+0.13pp
2016-12-31 -0.98% CN¥-61.90 Million
≈ $-9.06 Million
CN¥6.32 Billion
≈ $925.40 Million
-1.43pp
2015-12-31 0.45% CN¥28.10 Million
≈ $4.11 Million
CN¥6.26 Billion
≈ $915.72 Million
+0.54pp
2013-12-31 -0.09% CN¥-5.60 Million
≈ $-819.25K
CN¥6.14 Billion
≈ $897.87 Million
--
pp = percentage points

About Walvax BioTech

SHE:300142 China Drug Manufacturers - Specialty & Generic
Market Cap
$3.04 Billion
CN¥20.81 Billion CNY
Market Cap Rank
#4877 Global
#815 in China
Share Price
CN¥13.01
Change (1 day)
-2.84%
52-Week Range
CN¥10.91 - CN¥16.10
All Time High
CN¥93.63
About

Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China and internationally. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, grou… Read more